The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 13%Investors Business Daily • 09/12/23
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11GlobeNewsWire • 09/06/23
Anchored In Innovation: MoonLake Immunotherapeutics Charts A New Course (Rating Upgrade)Seeking Alpha • 08/28/23
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/10/23
August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An EdgeSeeking Alpha • 07/31/23
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readoutsGlobeNewsWire • 07/25/23
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary SharesGlobeNewsWire • 06/28/23
Why Mutual Fund Darling And Top 1% Stock MoonLake Immunotherapeutics Nearly DoubledInvestors Business Daily • 06/26/23
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativaGlobeNewsWire • 06/25/23
MoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 05/26/23
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/12/23
Here's Why Momentum in MoonLake Immunotherapeutics (MLTX) Should Keep goingZacks Investment Research • 05/10/23